Keywords
BV
erythrocyte deformability
ED
regression model
gasotransmitter donors
Full Text
Abstract
Summary. Introduction. A number of diseases and pathological conditions are accompanied by increased blood viscosity and, consequently, decreased tissue perfusion. Viscosity as an integral hemorheological feature depends on four main factors: plasma viscosity (PV), hematocrit (Hct), red blood cell deformability (RBCD), and red blood cell aggregation. However, only the last two RBC microrheological characteristics can be changed in a regulatory manner. Aim: to study the possibility of predicting blood viscosity (BV) and its fluidity using experimental in vitro and in silico models. Materials and Methods. Blood viscosity, viscosity of RBC suspension, PV, Hct, and RBC elongation index as RBCD were recorded in blood samples obtained from overweight individuals (group 2) and compared with the data of healthy individuals (group 1, controls). In vitro experiments with the use of gasotransmitter (GT) donors, sodium nitroprusside (SNP, 100 μM, NO donor) and sodium hydrosulfide (NaHS, 100 μM, H2S donor), increased RBCD by 7 and 11%, substituted these values into the regression equations “VK – RBCD” and obtained the predicted BV values (in silico model). Results. In group 2, BV exceeded this indicator in the control group by 23% (p < 0.05) due to increased PV and decreased RBCD. In the in vitro model of RBC microrheological responses to GT donors, RBCD increased by 7 and
11%. The relationship between blood viscosity and RBC deformability was satisfactorily described by the following regression equation: y = –10.69x + 39.17, where y is the BV, x is the RBCD. The solution to this equation, with the substitution of the RBCD value increased by 7 or 11% exposed to GT donors, yielded a predicted decrease in BV by 22% and 40%, respectively. Conclusion. The data showed that in over- weight individuals BV is 23% higher than in healthy individuals. In vitro model of RBC microrheological responses to GT donors showed a reliable increase in RBCD by 7 and 11% (p < 0.01). Using the regression model of the relationship between whole blood viscosity and RBCD, we could predict in silico how BV would change with an increase in RBCD. The solution of regression equations showed that the expected decrease in blood viscosity was 22 and 40%, respectively.
For citation: Muravyov A.V., Priezzhev A.V., Lugovtsov A.E., Tikhomirova I.A., Mikhaylov P.V., Osetrov I.A., Zamyshliaev A.V. Prediction of blood viscosity and fluidity: in vitro and in silico models experimental studies. Tromboz, gemostaz i reologiya. 2025;(4):21–28. (In Russ.).
References
1. Popel A.S., Johnson P.C. Microcirculation and Hemorheology. Annul Rev Fluid Mech. 2005;37:43–69. DOI: 10.1146/annurev. fluid.37.042604.133933.
2. Lipowsky H.H. Microvascular rheology and hemodynamics. Microcirculation. 2005;12(1):5–15. DOI: 10.1080/10739680590894966.
3. Dintenfass L. Clinical applications of heamorheology. The rheology
of blood, blood vessels and associated tissues. New York: Oxford
Press, 1981. 22–50.
4. Schmid‐Schönbein H. Antithixotropic therapy in arterial occlusive disorders: what is the effectiveness of “rheological procedures” in the presence of persisting obliterations? Wien Med Wochenschr. 1985;135(15–16):368–79. (In German).
5. Sandhagen B. Red cell fluidity in hypertension. Clin Hemorheol Microcirc. 1999;21(3–4):179–81.
6. Ajmani R.S. Hypertension and hemorheology. Clin Hemorheol Microcirc. 1997;17(6):397–420.
7. Fu G.‐X., Ji M., Han L.‐Z. et al. Erythrocyte rheological properties but not whole blood and plasma viscosity are associated with severity of hypertension in older people. Z Gerontol Geriatr. 2017;50(3):233–8. DOI: 10.1007/s00391‐016‐1039‐8.
8. Van Cromvoirt A.M., Fenk S., Sadafi A. et al. Donor age and red cell age contribute to the variance in Lorrca indices in healthy donors for next generation ektacytometry: a pilot study. Front Physiol. 2021;12:639722. DOI: 10.3389/fphys.2021.639722.
9. Pinho D., Carvalho V., Gonçalves I.M. et al. Visualization and measurements of blood cells flowing in microfluidic systems and blood rheology: a personalized medicine perspective. J Pers Med. 2020;10(4):249. DOI: 10.3390/jpm10040249.
10. Brunati M., Bordin L., Clari G., Moret V. The Lyn‐catalyzed Tyr phosphorylation of the transmembrane band 3 protein of human erythrocytes. Eur J Biochem. 1996;240:394–99. DOI: 10.1111/j.1432 ‐1033.1996.0394h.x.
11. Minetti G., Ciana A., Balduini C. Differential sorting of tyrosine kinases and phosphotyrosine phosphatases acting on band 3 during vesiculation of human erythrocytes. Biochem J. 2004;377(Pt 2):489– 97. DOI: 10.1042/BJ20031401.
12. Saldanha C., Silva A.S., Gonçalves S., Martins‐Silva J. Modulation of erythrocyte hemorheological properties by band 3 phosphorylation and dephosphorylation. Clin Hemorheol Microcirc. 2007;36(3):183– 94.
13. Ehrly M. Hemorheology, microcirculation and oxygenation. Phys‐ iopathological and therapeutic aspects. Rev Fr Gynecol Obstet. 1991;86(2 Pt 2):131–8. (In French).
14. Diederich L., Suvorava T., Sansone R. et al. On the effects of reactive oxygen species and nitric oxide on red blood cell deformability. Front Physiol. 2018;9:332. DOI: 10.3389/fphys.2018.00332.
15. Kobayashi J., Ohtake K., Murata I., Sonoda K. Nitric oxide bio‐ availability for red blood cell deformability in the microcircu‐ lation: a review of recent progress. Nitric Oxide. 2022;129:25–9. DOI: 10.1016/j.niox.2022.09.004.
16. An L., Ji F., Zhao E. et al. Measuring cell deformation by micro‐ fluidics. Front Bioeng Biotechnol. 2023;11:1214544. DOI: 10.3389/ fbioe.2023.1214544.
17. Förster E., Renz B. Methods of correlation and regression analysis. M.: Finance and Statistics, 1981. 302 p.
18. Stoltz J.F., Donner M., Muller S., Larcan A. Hemorheology in clinical practice. Introduction to the notion of hemorheologic profile. J Mal Vasc. 1991;16(3):261–70. (In French).
19. Muravyov A.V., Mikhailov P.V., Zinchuk V.V. et al. Hemorheological parameters in individuals with different levels of oxygen body supply: the effect of nitric oxide and hydrogen sulfide on erythrocyte microrheological characteristics. Tromboz, gemostaz i reologiya. 2021;(4):22–9. (In Russ.). DOI: 1025555/THR.2021.4.0993.
20. Mozar A., Connes P., Collins B. et al. Red blood cell nitric oxide synthase modulates red blood cell deformability in sickle cell anaemia. Clin Hemorheol Microcirc. 2016;64(1):47–53. DOI: 10.3233/CH162042.
21. Muravyov A.V., Tikhomirova I.A., Petrochenko E.P. et al. Effect of gasotransmitters donors (nitrogen oxide, hydrogen sulfide and carbon monoxide) on erythrocytes microrheological properties. Tromboz, gemostaz i reologiya. 2021;(1):68–73. (In Russ.). DOI: 10.25555/ THR.2021.1.0964.
22. Lew V.L., Tiffert T. On the mechanism of human red blood cell longevity: roles of calcium, the sodium pump, PIEZO1 and Gardos channels. Front Physiol. 2017;8:977. DOI: 10.3389/fphys.2017.00977. eCollection 2017.
23. Kuck L., Peart J. N., Simmonds M. J. Piezo1 regulates sheardependent nitric oxide production in human erythrocytes. Am J Physiol Heart Circ Physiol. 2022;323(1): H24–H37. DOI: 10.1152/ ajpheart.00185.2022.
24. Bor‐Kucukatay M., Wenby R.B., Meiselman H.J., Baskurt O.K. Effects of nitric oxide on red blood cell deformability. Am J Physiol Heart Circ Physiol. 2003;284(5): H1577–84. DOI: 10.1152/ajpheart.00665.2002.
25. Gheibi S., Jeddi S., Kashfi K., Ghasemi A. Regulation of vascular tone homeostasis by NO and H2S: Implications in hypertension. Biochem Pharmacol. 2018;149:42–59. DOI: 10.1016/j.bcp.2018.01.017.
26. Piragine E., Citi V., Lawson K., Calderone V., Martelli A. Potential effects of natural H2S‐donors in hypertension management. Biomolecules. 2022;12(4):58. DOI: 10.3390/biom12040581.
27. Rogers S., Lew V.L. Up‐down biphasic volume response of human red blood cells to PIEZO1 activation during capillary transits. PLoS Comput Biol. 2021;17(3): e1008706. DOI: 10.1371/journal. pcbi.1008706.
28. Meram E., Yilmaz B.D., Bas C. et al. Shear stress‐induced improvement of red blood cell deformability. Biorheology. 2013;50(3–4):165– 76. DOI: 10.3233/BIR‐130637.